Transaction #31703 · Form 4 · 0001437749-26-032240
Eton Pharmaceuticals, Inc. · Exercise / conversion · Common Stock
Eton Pharmaceuticals, Inc. · Transacted October 2, 2026 · Filed October 6, 2026
What does this filing report?
An SEC Form 4 filing for Eton Pharmaceuticals, Inc. records an exercise / conversion involving Common Stock on October 2, 2026. The reported quantity was 10,522. The filing date is October 6, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Eton Pharmaceuticals, Inc.
- Company CIK
- 0001710340
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 10,522
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 47,547
- Ownership description
- Not reported
- SEC acceptance time
- Oct 6, 2026, 4:49 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Krempa David ↗
Chief Business Officer
CIK 0001968254
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- F2
- The shares were sold in multiple trades at prices ranging from $54.915 to $55.135. The price reported above reflects the weighted average sales price.
- F3
- On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.